Covered recipient · General Payments record
TATIANA GANDRABURA
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
General Payments · PY2018–2024
$2,105.40
- Reported across 108 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $331.99 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $58.76 | 3 |
| Radius Health, Inc. | $49.54 | 1 |
| DEXCOM, INC. | $46.26 | 2 |
| Antares Pharma, Inc. | $43.72 | 2 |
| Lilly USA, LLC | $33.79 | 2 |
| Amneal Pharmaceuticals LLC | $32.83 | 2 |
| ABBVIE INC. | $19.60 | 1 |
| SANOFI-AVENTIS U.S. LLC | $17.51 | 1 |
| Tandem Diabetes Care, Inc. | $15.58 | 1 |
| IBSA Pharma Inc. | $14.40 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $19.60 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103770654 | CMS |
| Amneal Pharmaceuticals LLC | $17.11 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139186216 | CMS |
| Amneal Pharmaceuticals LLC | $15.72 | 11/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139186218 | CMS |
| Antares Pharma, Inc. | $26.99 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146459260 | CMS |
| Antares Pharma, Inc. | $16.73 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146459264 | CMS |
| Dexcom, Inc. | $21.28 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153339925 | CMS |
| Dexcom, Inc. | $24.98 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153339927 | CMS |
| IBSA Pharma Inc. | $14.40 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142972215 | CMS |
| Lilly USA, LLC | $15.69 | 02/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135436167 | CMS |
| Lilly USA, LLC | $18.10 | 09/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135474476 | CMS |
| Novo Nordisk Inc | $19.18 | 06/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097233893 | CMS |
| Novo Nordisk Inc | $20.27 | 10/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097808402 | CMS |
| Novo Nordisk Inc | $19.31 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096901477 | CMS |
| Radius Health, Inc. | $49.54 | 05/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089996859 | CMS |
| SANOFI-AVENTIS U.S. LLC | $17.51 | 08/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139720246 | CMS |
| Tandem Diabetes Care, Inc. | $15.58 | 03/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138738779 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.